London · Delayed Price · Currency is GBP · Price in GBX Victrex Earnings Call Transcripts
Fiscal Year 2026
-
H1 saw modest revenue growth and strong cash flow, but margins and profits declined due to price and mix pressures. A major China plant impairment and restructuring are underway, with a new decentralized model and profit improvement plan expected to drive better performance in H2 and beyond.
Fiscal Year 2025
-
FY 2025 saw strong volume growth but limited revenue gains due to currency and mix, with profit down and robust cash conversion. A profit improvement plan aims for GBP 10 million in savings, while FY 2026 guidance targets moderate growth, margin stability, and continued CapEx discipline.
-
Q3 saw 8% volume growth but a 3% revenue decline due to adverse mix and medical weakness. Full-year volume guidance remains high single digits, with currency and medical spine headwinds impacting outlook. CEO transition and China facility progress highlighted.
-
H1 2025 saw 16% volume growth and strong cash conversion, but gross margin and ASP declined due to mix and China ramp-up costs. Upgraded full-year volume guidance to high single digits, with medical and Magma programs expected to drive future growth.
Fiscal Year 2024
-
Volumes grew 4% in FY 2024, but revenue fell 5% due to medical destocking and lower asset utilization, leading to a 26% drop in underlying PBT. Strong cash conversion and reduced CapEx position the business for mid-single-digit volume growth and margin improvement in FY 2025.
-
Q3 2024 saw 20% volume and 2% revenue growth year-over-year, driven by VAR and electronics, while medical remained weak due to industry destocking. Free cash flow improved, and full-year guidance for low to mid-single-digit volume growth is maintained.